← All trials
NCT03246529
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2018
- Primary completion
- Apr 22, 2019
- Completion date
- Sep 22, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 207
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BioLineRx, Ltd.Lead sponsor
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.